FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2510141057> ?p ?o ?g. }

• W2510141057 endingPage "1352" @default.
• W2510141057 startingPage "1339" @default.
• W2510141057 abstract "Survivin is an anti-apoptotic protein that is highly expressed in many cancers, including malignant gliomas. Preclinical studies established that the conjugated survivin peptide mimic SurVaxM (SVN53-67/M57-KLH) could stimulate an anti-tumor immune response against murine glioma in vivo, as well as human glioma cells ex vivo. The current clinical study was conducted to test safety, immunogenicity and clinical effects of the vaccine. Recurrent malignant glioma patients whose tumors were survivin-positive, and who had either HLA-A*02 or HLA-A*03 MHC class I allele-positivity, were given subcutaneous injections of SurVaxM (500 μg) in Montanide ISA 51 with sargramostim (100 μg) at 2-week intervals. SurVaxM was well tolerated with mostly grade one adverse events (AE) and no serious adverse events (SAE) attributable to the study drug. Six patients experienced local injection site reactions; three patients reported fatigue (grades 1 and 2), and 2 patients experienced myalgia (grade 1). Six of eight immunologically evaluable patients developed both cellular and humoral immune responses to vaccine. The vaccine also stimulated HLA-A*02, HLA-A*03 and HLA-A*24 restricted T cell responses. Three patients maintained a partial clinical response or stable disease for more than 6 months. Median progression-free survival was 17.6 weeks, and median overall survival was 86.6 weeks from study entry with seven of nine patients surviving more than 12 months." @default.
• W2510141057 created "2016-09-16" @default.
• W2510141057 creator A5003545380 @default.
• W2510141057 creator A5018341423 @default.
• W2510141057 creator A5035416012 @default.
• W2510141057 creator A5036910737 @default.
• W2510141057 creator A5045773131 @default.
• W2510141057 creator A5050227848 @default.
• W2510141057 creator A5053202206 @default.
• W2510141057 creator A5059830806 @default.
• W2510141057 creator A5063612627 @default.
• W2510141057 creator A5069146590 @default.
• W2510141057 date "2016-08-30" @default.
• W2510141057 modified "2023-10-17" @default.
• W2510141057 title "Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma" @default.
• W2510141057 cites W147472336 @default.
• W2510141057 cites W1521397874 @default.
• W2510141057 cites W1549487237 @default.
• W2510141057 cites W1590471414 @default.
• W2510141057 cites W1662899239 @default.
• W2510141057 cites W1858161324 @default.
• W2510141057 cites W1893157084 @default.
• W2510141057 cites W1930737617 @default.
• W2510141057 cites W1973414104 @default.
• W2510141057 cites W1974620735 @default.
• W2510141057 cites W1988402476 @default.
• W2510141057 cites W1995257401 @default.
• W2510141057 cites W1997062019 @default.
• W2510141057 cites W2018114565 @default.
• W2510141057 cites W2035523654 @default.
• W2510141057 cites W2073323116 @default.
• W2510141057 cites W2076186796 @default.
• W2510141057 cites W2085616056 @default.
• W2510141057 cites W2085687864 @default.
• W2510141057 cites W2086601270 @default.
• W2510141057 cites W2094294085 @default.
• W2510141057 cites W2096230274 @default.
• W2510141057 cites W2106031844 @default.
• W2510141057 cites W2120408259 @default.
• W2510141057 cites W2134877501 @default.
• W2510141057 cites W2138733343 @default.
• W2510141057 cites W2142614342 @default.
• W2510141057 cites W2149008396 @default.
• W2510141057 cites W2149768128 @default.
• W2510141057 cites W2161289668 @default.
• W2510141057 cites W2167457277 @default.
• W2510141057 cites W4249233937 @default.
• W2510141057 doi "https://doi.org/10.1007/s00262-016-1890-x" @default.
• W2510141057 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5069322" @default.
• W2510141057 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27576783" @default.
• W2510141057 hasPublicationYear "2016" @default.
• W2510141057 type Work @default.
• W2510141057 sameAs 2510141057 @default.
• W2510141057 citedByCount "97" @default.
• W2510141057 countsByYear W25101410572017 @default.
• W2510141057 countsByYear W25101410572018 @default.
• W2510141057 countsByYear W25101410572019 @default.
• W2510141057 countsByYear W25101410572020 @default.
• W2510141057 countsByYear W25101410572021 @default.
• W2510141057 countsByYear W25101410572022 @default.
• W2510141057 countsByYear W25101410572023 @default.
• W2510141057 crossrefType "journal-article" @default.
• W2510141057 hasAuthorship W2510141057A5003545380 @default.
• W2510141057 hasAuthorship W2510141057A5018341423 @default.
• W2510141057 hasAuthorship W2510141057A5035416012 @default.
• W2510141057 hasAuthorship W2510141057A5036910737 @default.
• W2510141057 hasAuthorship W2510141057A5045773131 @default.
• W2510141057 hasAuthorship W2510141057A5050227848 @default.
• W2510141057 hasAuthorship W2510141057A5053202206 @default.
• W2510141057 hasAuthorship W2510141057A5059830806 @default.
• W2510141057 hasAuthorship W2510141057A5063612627 @default.
• W2510141057 hasAuthorship W2510141057A5069146590 @default.
• W2510141057 hasBestOaLocation W25101410571 @default.
• W2510141057 hasConcept C121608353 @default.
• W2510141057 hasConcept C126322002 @default.
• W2510141057 hasConcept C143998085 @default.
• W2510141057 hasConcept C147483822 @default.
• W2510141057 hasConcept C195616568 @default.
• W2510141057 hasConcept C197934379 @default.
• W2510141057 hasConcept C203014093 @default.
• W2510141057 hasConcept C2775975398 @default.
• W2510141057 hasConcept C2776789287 @default.
• W2510141057 hasConcept C2778227246 @default.
• W2510141057 hasConcept C2780868878 @default.
• W2510141057 hasConcept C502942594 @default.
• W2510141057 hasConcept C71924100 @default.
• W2510141057 hasConcept C8891405 @default.
• W2510141057 hasConcept C90924648 @default.
• W2510141057 hasConceptScore W2510141057C121608353 @default.
• W2510141057 hasConceptScore W2510141057C126322002 @default.
• W2510141057 hasConceptScore W2510141057C143998085 @default.
• W2510141057 hasConceptScore W2510141057C147483822 @default.
• W2510141057 hasConceptScore W2510141057C195616568 @default.
• W2510141057 hasConceptScore W2510141057C197934379 @default.
• W2510141057 hasConceptScore W2510141057C203014093 @default.
• W2510141057 hasConceptScore W2510141057C2775975398 @default.
• W2510141057 hasConceptScore W2510141057C2776789287 @default.
• W2510141057 hasConceptScore W2510141057C2778227246 @default.

• next